Meeting
2021 ASCO Annual Meeting
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.
Presenter
Katherine Tarlock, MD
Seattle Children's Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Clinical Trial Registration Number
NCT03813147
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10018)
DOI
10.1200/JCO.2021.39.15_suppl.10018
Abstract #
10018
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2019 ASCO Annual Meeting
AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A Report from the Children’s Oncology Group.
Speaker: Todd Michael Cooper, DO
Videos & Slides
2018 ASCO Annual Meeting
Initial results of two phase I trials delivering mbIL-21 ex vivo expanded haploidentical NK cells after fludarabine/cytarabine for patients with relapsed/refractory myeloid leukemias.
Speaker: Stefan O. Ciurea, MD
Speaker: Bruce E. Johnson, MD, FASCO
Speaker: Panel Discussion